Heart drugs ineffective in treating pulmonary arterial hypertension

Despite their beneficial effects in treating heart disease, neither aspirin nor simvastatin appear to offer benefit to patients suffering from pulmonary artery hypertension (PAH), according to a National Institutes of Health (NIH)-funded study conducted at four U.S. medical centers. This was the first NIH-funded randomized clinical trial (RCT) in PAH.

The results of the study will be presented at the ATS 2011 International Conference in Denver.

PAH is a progressive, incurable disease characterized by increased blood pressure in the arteries of the lungs, which causes shortness of breath, dizziness and fatigue, and can lead to and death. PAH can occur on its own or be associated with other conditions, such as connective tissue diseases and .

Although both aspirin and simvastatin are effective in many types of cardiovascular disease, these drugs have not been well-studied in the treatment of PAH, said Steven Kawut, MD, MS lead author and associate professor of medicine and epidemiology at the University of Pennsylvania School of Medicine. The study was designed to determine if the drugs could be effective in the treatment of patients with PAH.

"Surprisingly, we found no evidence that aspirin or simvastatin had beneficial clinical effects in this population, and the study was terminated early by the National Heart Lung and Blood Institute upon the recommendation of the Data and Safety Monitoring Board (DSMB)," said Dr. Kawut, who is also director of the university's Pulmonary Vascular Disease Program. "The results of this study do not support the routine treatment of PAH with these medications."

Researchers enrolled 65 patients in this placebo-controlled trial and randomized them into four groups: one in which patients received aspirin, one in which patients received simvastatin, one in which patients received both drugs, and one in which patients received neither drug. The main outcome, six-minute walk distance (6MWD) (a measure of how far a person can walk in six minutes), tended to be lower in the group taking simvastatin at six months. Based on these early results, the DSMB recommended stopping the study since there was a low probability of demonstrating a beneficial effect of simvastatin even if the study enrolled the planned number of subjects (92). There was no significant difference in the 6MWD between the group taking aspirin and the group taking placebo.

"Multiple animal studies have suggested that simvastatin would be effective in PAH, and aspirin has biologic effects which would be expected to benefit PAH patients," Dr. Kawut said. "This study demonstrates that federally-funded, investigator-initiated RCTs in PAH and other pulmonary vascular diseases are feasible. The findings show the importance of subjecting traditional cardiovascular therapies and drugs which appear effective in the laboratory to placebo-controlled RCTs in humans before recommending their use."

" and simvastatin may be prescribed for usual clinical indications in patients with PAH, but should not be administered specifically to treat PAH," he added.

add to favorites email to friend print save as pdf

Related Stories

Gene therapy may be effective in treating PAH

May 19, 2010

Gene therapy has been shown to have positive effects in rat models of pulmonary arterial hypertension (PAH), according to researchers at the University of Adelaide in Australia.

Researchers revisit pulmonary arterial hypertension survival

Jan 05, 2010

Setting out to determine the survival of patients with pulmonary arterial hypertension (PAH), researchers at the University of Chicago Medical Center and their colleagues also discovered that an equation used for more than ...

Recommended for you

Exercise may protect older women from irregular heartbeat

8 hours ago

Increasing the amount or intensity of physical activity can cut the chances of older women developing a life-threatening irregular heartbeat, according to new research in the Journal of the American Heart Association (JAHA).

Huge discrepancies on heart disease in Europe

20 hours ago

Russians and Ukrainians aged 55 to 59 die from coronary heart disease at a higher rate than Frenchmen who are 20 years older, a study released Wednesday of Europe's cardiovascular health showed.

Common antibiotic linked with heart deaths

Aug 19, 2014

The antibiotic clarithromycin—widely used for treating common bacterial infections—is associated with an increased risk of heart deaths, finds a study published in the BMJ today.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

dogbert
not rated yet May 18, 2011
I wonder why anyone thought that aspirin or statins would be beneficial in PAH. Neither drug affects blood pressure and statins should be expected to lower walking distance (as they did) due to lowered metabolism.

Something like Cialis might be expected to lower PAH.